HomeCompareELMSQ vs ABBV

ELMSQ vs ABBV: Dividend Comparison 2026

ELMSQ yields 1481.48% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELMSQ wins by $626785561.35M in total portfolio value
10 years
ELMSQ
ELMSQ
● Live price
1481.48%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$626785561.46M
Annual income
$553,314,905,198,340.25
Full ELMSQ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ELMSQ vs ABBV

📍 ELMSQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELMSQABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELMSQ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELMSQ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELMSQ
Annual income on $10K today (after 15% tax)
$125,925.93/yr
After 10yr DRIP, annual income (after tax)
$470,317,669,418,589.20/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ELMSQ beats the other by $470,317,669,397,533.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELMSQ + ABBV for your $10,000?

ELMSQ: 50%ABBV: 50%
100% ABBV50/50100% ELMSQ
Portfolio after 10yr
$313392780.78M
Annual income
$276,657,452,611,556.00/yr
Blended yield
88.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ELMSQ
Analyst Ratings
5
Hold
Consensus: Hold
Altman Z
0.0
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELMSQ buys
0
ABBV buys
0
No recent congressional trades found for ELMSQ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELMSQABBV
Forward yield1481.48%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$626785561.46M$102.3K
Annual income after 10y$553,314,905,198,340.25$24,771.77
Total dividends collected$621430185.90M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: ELMSQ vs ABBV ($10,000, DRIP)

YearELMSQ PortfolioELMSQ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$158,848$148,148.15$11,550$430.00+$147.3KELMSQ
2$2,369,319$2,199,351.31$13,472$627.96+$2.36MELMSQ
3$33,193,761$30,658,589.95$15,906$926.08+$33.18MELMSQ
4$436,939,498$401,422,173.47$19,071$1,382.55+$436.92MELMSQ
5$5,405,881,572$4,938,356,308.99$23,302$2,095.81+$5405.86MELMSQ
6$62,885,313,260$57,101,019,978.27$29,150$3,237.93+$62885.28MELMSQ
7$688,074,536,789$620,787,251,600.62$37,536$5,121.41+$688074.50MELMSQ
8$7,084,361,831,143$6,348,122,076,778.87$50,079$8,338.38+$7084361.78MELMSQ
9$68,664,164,726,111$61,083,897,566,788.09$69,753$14,065.80+$68664164.66MELMSQ
10$626,785,561,455,279$553,314,905,198,340.25$102,337$24,771.77+$626785561.35MELMSQ

ELMSQ vs ABBV: Complete Analysis 2026

ELMSQStock

Electric Last Mile Solutions, Inc., a commercial electric vehicle solutions company, focuses on designing, engineering, manufacturing, and customizing electric 'last mile' delivery and utility vehicles. It offers Class 1 commercial electric vehicle in the U.S. market and focuses on producing Class 3 Urban Utility electric vehicle. The company is headquartered in Troy, Michigan. On June 14, 2022, Electric Last Mile Solutions, Inc., along with its affiliate, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Full ELMSQ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ELMSQ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELMSQ vs SCHDELMSQ vs JEPIELMSQ vs OELMSQ vs KOELMSQ vs MAINELMSQ vs JNJELMSQ vs MRKELMSQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.